ReviewMelanoma in Immunosuppressed Patients
Section snippets
Melanoma-Induced Immunosuppression
Within the biology of cancer, suppression of the normal immune response is pivotal in the ability of tumors to grow and metastasize. Cutaneous melanoma is an immunogenic tumor with the ability to spread via the lymphatic system while simultaneously evading and overcoming the body's tumor surveillance system.8 Melanoma-induced immunosuppression develops through numerous mechanisms, such as down-regulation of surface antigens, mutations within malignant cells, lack of costimulatory function,
The Melanoma Microenvironment
In normal physiologic responses, regulatory CD4+CD25+ T cells allow for development of peripheral immune tolerance; without these molecules, autoimmune reactions occur. In melanoma, these regulatory cells secrete immunosuppressive cytokines and suppress activation and proliferation of the antitumor immune response9, 10 (Boon et al 1997, Romero et al 1998, as cited in Viguier et al11). These regulatory CD4+CD25+ T cells express FOXP3 and have been associated with failed clinical responses of
Melanoma and the Sun
The medical literature shows a consensus that extensive exposure to UV radiation is a risk factor for melanoma.19 Although the exact mechanism is not clear, experts have speculated that the combination of carcinogenic, inflammatory, and immunosuppressive elements of UV radiation contribute to this risk.19 The mechanism involves keratinocyte response to UV radiation, which induces melanocyte production of melanin.19 Ultraviolet radiation is a potent mutagen in keratinocyte DNA and has the
Melanoma in Solid Organ Transplant Recipients
Solid organ transplant recipients are a well-studied group of immunocompromised patients. Among these individuals, an increased incidence of both nonmelanoma skin cancer and melanoma has been reported extensively. Herein, we review the data on melanomas occurring after transplant. In addition, we elaborate on the clinical scenarios of patients with a history of melanoma before transplant and melanoma that resulted from transmission from the organ donor.25
Melanoma in Lymphoproliferative Disease
Another group of immunocompromised patients are those with lymphoproliferative disorders. The incidence of not only melanoma but also lymphoma has increased in recent decades, making both these cancers particularly relevantāespecially the overlap that exists between the 2 entities. Substantial literature chronicles melanoma in NHL and chronic lymphocytic leukemia (CLL) in particular; however, as in OTRs, much of the research thus far has focused on mechanisms of disease and incidence, with
Melanoma and Iatrogenic Immunosuppression
Within the larger spectrum of immunosuppression, iatrogenic causes are an important consideration, especially with the use of medications that suppress immune function. Whether these medications create a preferred environment for melanoma carcinogenesis or whether melanoma development is attributable to the direct effects of the medication is unclear.41 Of these medications, cyclosporine A, azathioprine, mycophenolate mofetil, corticosteroids, methotrexate, tacrolimus, 5-fluorouracil, and
Melanoma in Patients With Hiv Infection/Aids
Since the advent of highly active antiretroviral therapy (HAART), survival rates of patients infected with HIV have improved dramatically, which has altered the disease course.89 HAART typically constitutes 3 or more medications that act through different HIV-attacking mechanisms. The number of AIDS-defining lesions and infections has decreased since the advent and frequent use of HAART in the mid-1990s. Still, the number has increased of chronic diseases that manifest because of adverse
Recommendations
Evidence-based decision making is limited in the care of immunosuppressed patients with melanoma. In general, treatment of immunocompromised patients should parallel the treatments of the immunocompetent population. Surgical excision typically is curative in early melanomas; therefore, vigilant screening and appropriate education are key for the immunocompromised population, in whom melanomas are not only more frequent but also have been shown to behave more aggressively.5, 94 In addition, a
Conclusion
Melanoma-induced immunosuppression and tumor evasion of normal immunologic reactions lead to the ability of melanoma to hide from the immune response. As melanoma incidence increases, populations of both OTRs and patients with lymphoproliferative disease grow, and patients with HIV infection live longer, there is also an increased need to learn about and understand the natural history, prognosis, and management of melanoma in the immunocompromised host. Although some literature about melanoma
References (98)
- et al.
Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases
Am J Transplant
(2008) - et al.
Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells
J Surg Res
(2007) - et al.
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Blood
(2009) - et al.
The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles: possible contribution to tumor counterattack
Exp Cell Res
(2004) - et al.
Skin cancer in liver transplant recipients
Liver Transplant
(2000) - et al.
Cancer risk in patients on dialysis and after renal transplantation
Lancet
(2000) - et al.
Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens
J Am Acad Dermatol
(1999) - et al.
Cancer after kidney transplantation in the United States
Am J Transplant
(2004) - et al.
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Lancet
(2007) - et al.
Prognosis of pretransplant melanoma
Am J Transplant
(2009)
Outcomes of melanoma in recipients of solid organ transplant
J Am Acad Dermatol
Transmission of donor melanoma by organ transplantation
Lancet Oncol
Melanoma in solid organ transplant recipients
Am J Transplant
Malignant melanoma in renal-transplant recipients
Lancet
Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy
J Am Acad Dermatol
An association between cutaneous melanoma and non-Hodgkin's lymphoma: pooled analysis of published data with a review
Ann Oncol
Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer
Int J Radiat Oncol Biol Phys
Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia
Blood
Solid tumors after chronic lymphocytic leukemia
Blood
Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study
J Am Acad Dermatol
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time
Ann Oncol
Cutaneous malignancy and human immunodeficiency virus disease
J Am Acad Dermatol
Melanoma and immunosuppression
Dermatology
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
Cancer
Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma
Immunol Cell Biol
Complete regression of primary cutaneous malignant melanoma
Arch Surg
Malignant melanoma in solid transplant recipients: collection of database cases and comparison with Surveillance, Epidemiology, and End Results data for outcome analysis
Arch Dermatol
Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study
J Clin Oncol
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation
Oncologist
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients
Ann Surg Oncol
Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells
J Immunol
Mechanisms of local immunosuppression in cutaneous melanoma
Br J Cancer
Next generation of immunotherapy for melanoma
J Clin Oncol
TAP expression reduces IL-10 expressing tumor infiltrating lymphocytes and restores immunosurveillance against melanoma
Int J Cancer
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion [published correction appears in Nat Med. 2002;8(9):1039]
Nat Med
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity
Cancer Res
How sunlight causes melanoma
Curr Oncol Rep
Skin cancers after organ transplantation
N Engl J Med
Cancer risk following organ transplantation: a nationwide cohort study in Sweden
Br J Cancer
Incidence of skin cancer in 5356 patients following organ transplantation
Br J Dermatol
Melanoma in immunosuppressed patients [editorial]
Exp Rev Dermatol
Cutaneous melanoma is related to immune suppression in kidney transplant recipients
Cancer Epidemiol Biomarkers Prev
A population-based study of skin cancer incidence and prevalence in renal transplant recipients
Br J Dermatol
Melanomas in renal transplant recipients
Br J Dermatol
Cancer incidence before and after kidney transplantation
JAMA
Increased incidence of melanoma in renal transplantation recipients
Cancer
Cancer report
Melanoma in organ transplant patients [in French]
Ann Dermatol Venereol
Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data
Transplantation
Cited by (98)
Cutaneous melanoma
2023, The LancetCXCL10-coronated thermosensitive āstealthā liposomes for sequential chemoimmunotherapy in melanoma
2023, Nanomedicine: Nanotechnology, Biology, and MedicineTemporal bone mucosal melanoma masquerading as otomastoiditis
2022, Otolaryngology Case ReportsCitation Excerpt :This association may explain the metachronous relationship between lymphoproliferative diseases, such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with malignant melanoma [10,11]. It is important to note that this link between lymphoproliferative disease and melanoma is bidirectional, and individuals with malignant melanomas have been observed to have higher incidence rates for lymphoproliferative disorders [12]. Furthermore, patient outcomes have been noted to be worse in individuals diagnosed with both melanoma and NHL when compared to that of patients with a singular diagnosis [13].
Evidence concerning the accusation that melanoma is overdiagnosed
2021, Journal of the American Academy of DermatologyThe Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies
2021, Clinical Gastroenterology and Hepatology
Grant Support: Dr Jerry D. Brewer is the recipient of the Dermatology Foundation Career Development Award for the study of lymphoma-associated skin cancer.